Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.550
-0.080 (-4.91%)
At close: Aug 1, 2025, 4:00 PM
1.550
0.00 (0.00%)
Pre-market: Aug 4, 2025, 5:02 AM EDT

Company Description

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases.

It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease.

In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma.

Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer.

Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals logo
CountryIsrael
Founded2000
IPO DateMar 13, 2014
IndustryBiotechnology
SectorHealthcare
Employees6
CEOAllen Baharaff

Contact Details

Address:
16 Abba Hillel Road
Ramat Gan, 5250608
Israel
Phone972 3 693 8448
Websitegalmedpharma.com

Stock Details

Ticker SymbolGLMD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001595353
CUSIP NumberM47238106
ISIN NumberIL0011313900
Employer ID98-1147233
SIC Code2834

Key Executives

NamePosition
Allen BaharaffCo-Founder, President, Chief Executive Officer and Chairman
Doron CohenChief Financial Officer
Guy NehemyaChief Operating Officer and Data Protection Officer
Yohai Stenzler CPAChief Accounting Officer
Dr. Liat Hayardeny MBA, Ph.D.Chief Scientific Officer
Dr. Tali GorfineMedical Consultant

Latest SEC Filings

DateTypeTitle
Jul 24, 20256-KReport of foreign issuer
May 27, 20256-KReport of foreign issuer
May 22, 20256-KReport of foreign issuer
May 13, 20256-KReport of foreign issuer
May 6, 20256-KReport of foreign issuer
Apr 28, 20256-KReport of foreign issuer
Apr 17, 20256-KReport of foreign issuer
Apr 15, 20256-KReport of foreign issuer
Apr 10, 20256-KReport of foreign issuer
Apr 8, 2025EFFECTNotice of Effectiveness